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ABSTRACT (word count: 245) 
Objective: Gastric colonization with Helicobacter pylori is a strong risk factor for non-cardia 
gastric adenocarcinoma. The aim of this study was to assess whether the risk of gastric 
adenocarcinoma and non-cardia gastric adenocarcinoma decreases after eradication treatment 
for Helicobacter pylori in a Western population.  
Design: This was a nationwide, population-based cohort study in Sweden in 2005-2012. Data 
from the Swedish Prescribed Drug Registry provided information on Helicobacter pylori 
eradication treatment whereas information concerning newly developed gastric 
adenocarcinoma was retrieved from the Swedish Cancer Registry. The risk of gastric 
adenocarcinoma and non-cardia gastric adenocarcinoma in individuals who had received 
Helicobacter pylori eradication treatment was compared with the background population of 
the corresponding age, sex and calendar year distribution, yielding standardized incidence 
ratios (SIRs) with 95% confidence intervals (95% CIs).  
Results: During the follow-up of 95,176 individuals who had received eradication treatment 
(351,018 person-years at risk), 75 (0.1%) developed gastric adenocarcinoma and 69 (0.1%) 
developed non-cardia gastric adenocarcinoma. The risk of gastric adenocarcinoma decreased 
over time after eradication treatment to levels below that of the corresponding background 
population. The SIRs were 8.65 (95% CI 6.37-11.46) 1-3 years, 2.02 (95% CI 1.25-3.09) 3-5 
years, and 0.31 (95% CI 0.11-0.67) 5-7.5 years after eradication treatment. When restricted to 
non-cardia adenocarcinoma, the corresponding SIRs were 10.74 (95% CI 7.77-14.46), 2.67 
(95% CI 1.63-4.13), and 0.43 (95% CI 0.16-0.93).    
Conclusion: Eradication treatment for Helicobacter pylori seems to counteract the 
development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this 
Western population. 
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SIGNIFICANCE OF THIS STUDY 
What is already known about this subject? 
 The strongest risk factor for non-cardia gastric adenocarcinoma is gastric colonisation 
with Helicobacter pylori.  
 Only a small percentage (3%) of those colonised with Helicobacter pylori develop 
non-cardia gastric adenocarcinoma.  
 Eradication of Helicobacter pylori is associated with a reduced risk of gastric cancer 
in Asian populations.  
What are the new findings? 
 This study assessed the role of Helicobacter pylori eradication treatment in the 
prevention of gastric adenocarcinoma in a large population-based study, using data 
from high-quality nationwide Swedish registers. 
 The risk of gastric adenocarcinoma (non-cardia adenocarcinoma in particular) sharply 
decreased from 5 years onwards after eradication treatment for Helicobacter pylori.  
How might it impact on clinical practice in the foreseeable future? 
 The findings of this study may contribute to a better understanding of the risks and 
benefits of eradication therapy in regions with a low prevalence of gastric cancer.  
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INTRODUCTION 
Globally, gastric cancer (95% adenocarcinoma) is the fifth most common cancer (incidence 
rate 16.1 per 100,000 individuals) and the second most common cause of cancer death (death 
rate 13.8 per 100,000 individuals).
1
 The highest incidence is found in Asian populations, and 
the lowest in Western populations.
1
 In Sweden (a Western population), the incidence rates are 
10.4 and 6.4 per 100,000 individuals in men and women, respectively.
2
 Colonization with the 
bacterium Helicobacter pylori (H. pylori) is associated with an increased risk of non-cardia 
gastric adenocarcinoma, whereas the risk of cardia gastric adenocarcinoma is not increased.
3
 
Worldwide, around half of the population is colonized, with higher rates in Asia and Central 
and South America, and lower rates in Western populations.
4
 The H. pylori prevalence in 
Sweden is around 15%, which is relatively low.
5
 Of those colonized, it is estimated that the 
lifetime risk of developing gastric adenocarcinoma is around 3%.
6
  
H. pylori eradication, mainly used for the prevention of recurrent peptic ulcer after an earlier 
ulcer episode, has been found to prevent gastric cancer in meta-analyses, showing a 50% risk 
reduction.
7,8
 However, these meta-analyses almost exclusively included studies from Asian 
populations and the individual studies had small sample sizes. Thus, there is a need to 
estimate the role of H. pylori eradication treatment in the prevention of gastric cancer in large-
scale studies from Western populations with specific analyses of the risk of non-cardia 
adenocarcinoma. Therefore, this study aimed to assess the risk of gastric adenocarcinoma and 
of non-cardia gastric adenocarcinoma after eradication treatment for H. pylori in a nationwide 
Swedish cohort study.  
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MATERIALS AND METHODS 
Study design 
This was a population-based, nationwide cohort study in Sweden, based on an a priori 
established study protocol. The exposure was eradication treatment for H. pylori and the 
outcomes were gastric adenocarcinoma and non-cardia gastric adenocarcinoma. Eligible for 
inclusion were all individuals residing in Sweden aged 18 years and older who received 
eradication treatment for H. pylori during July 1
st
, 2005 to December 31
st
, 2012. The cohort 
has been described in more detail elsewhere.
9
 The study was approved by the Regional 
Ethical Review Board in Stockholm (2014/1291-31/4). 
 
Exposure 
Individuals were considered exposed if they received at least one prescription and dispensing 
of a recommended eradication regimen for H. pylori. Eradication treatment for H. pylori in 
Sweden usually consists of a combination of a proton pump inhibitor together with the 
antibiotics amoxicillin and clarithromycin for 7 days.
9
 The following prescriptions are 
available in Sweden for recommended eradication treatment of H. pylori (specified by the 
Anatomical Therapeutic Chemical code): 
- A specific H. pylori eradication  package that includes the proton pump inhibitor 
esomeprazole and the antibiotics amoxicillin and clarithromycin (A02BD06); 
- Separate prescriptions of a proton pump inhibitor (A02BC) together with 2 of the 
following antibiotics: amoxicillin (J01CA04) and clarithromycin (J01FA09) or 
metronidazole (J01XD01).  
For the separate prescriptions, no other antibiotics were to be prescribed at the same time in 
order to be considered a recommended regimen. Additionally, the antibiotics had to be 
prescribed on the exact same date, whereas the proton pump inhibitor was allowed to be 
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prescribed within a window of 60 days before or 5 days after the antibiotics prescription. This 
window was chosen to include individuals already using a proton pump inhibitor before the 
eradication treatment, and to take temporary non-availability in the pharmacy into account. 
Recommended eradication regimens accounted for 95.4% of all eradication treatments 
prescribed in Sweden during the study period.
9
 The remaining 4.6% of the treatments 
included combinations of antibiotics that are not standard for H. pylori eradication and were 
therefore not included in this study.   
 
Outcomes 
The outcomes were first and primary gastric adenocarcinoma and non-cardia gastric 
adenocarcinoma diagnosed in the Swedish Cancer Registry during follow-up of the cohort 
after H. pylori eradication treatment, excluding tumours occurring within 1 year of the 
eradication treatment. Gastric cancer was defined by any of the following ICD7 codes: 151, 
151.0, 151.1, 151.8 and 151.9, whereas the code for cardia cancer (151.1) was excluded when 
analysing non-cardia cancer. Adenocarcinoma histology was determined using the code 096 
from the C24 World Health Organization classification of histology. Other histological types 
of gastric malignancies are not associated with H. pylori (or have a different level of 
association, e.g. mucosa-associated lymphoid tissue lymphoma), and therefore were 
excluded.
10
   
 
Confounders 
Adjustments were made for age (categorized into the age groups 18-59, 60-69, or ≥70 years), 
sex (men or women), and calendar period (2005-2006, 2007-2009, or 2010-2012) by 
standardizing these variables. Place of residence (urban or rural), which is correlated with 
socioeconomic and lifestyle factors,
11
 was analysed for influence on the outcome.  
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Data sources 
The Swedish Prescribed Drug Registry provided information on H. pylori eradication 
treatment. This register started on July 1, 2005 and contains information on all prescribed and 
dispensed medications for the whole Swedish population. Patient identifying data are missing 
in only <0.3% of all recorded prescriptions.
12
 Variables used were the age, sex, postal code 
(to assess place of residence),
11
 unique personal identity number of each individual, and the 
substance, dates, amount and dosage of the dispensed drugs.  
The Swedish Cancer Registry provided information on gastric and non-cardia gastric 
adenocarcinoma. This register has a completeness of 98% for recording of non-cardia 
adenocarcinoma.
13
 Data on the histological type and location of the cancer, and date and age 
at cancer diagnosis was used, and all these variables are 100% completely recorded in the 
register.  
The Swedish Causes of Death Registry was used to assess dates of death. This information is 
virtually 100% complete and was used for censoring of follow-up time.
14
   
 
Statistical analysis 
Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were calculated as 
the ratio of the observed number of gastric and non-cardia gastric adenocarcinoma cases in 
the H. pylori eradication cohort, compared to the expected number of such cases in the 
Swedish population of the same sex, age group, and calendar period with categorization as 
presented above (subtitle “Confounders”). Clayton’s algorithm was used to calculate the 
follow-up time in person-years for each stratum, starting from the date of the first dispensed 
prescription of H. pylori eradication treatment.
15
 This index date was chosen as time zero to 
emulate a randomized clinical trial.
16
 Additionally, a “per-protocol” analysis was performed 
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which started from the last dispense date of eradication treatment. Individuals were followed 
up until the occurrence of any cancer, death, or the end of the study period, whichever 
occurred first. Subgroup analyses were performed for the time after eradication treatment 
(grouped into 1-3, 3-5, and 5-7.5 years), and the number of received eradication treatments (1, 
2, and ≥ 2). More than 1 eradication treatment indicated that H. pylori remained present after 
the previous treatment attempt, thus prolonging the colonization time in the individual.   
Poisson regression was used to analyse potential confounding by place of residence (urban or 
rural), and to assess any influence of the length of follow-up, presented as incidence rate 
ratios (IRRs) and 95% CIs. The statistical software STATA (Stata Corp v. 13.0, College 
Station, TX) was used for all analyses.   
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RESULTS 
Participants 
The study included 95,176 individuals receiving H. pylori eradication treatment during the 
study period (Table 1). There were more men (53.7%) than women (46.3%) and the majority 
was younger than 60 years (60.1%). Most individuals resided in urban areas (74.6%). The 
mean length of follow-up was 3.7 years (maximum 7.5 years). During 351,018 person-years 
at risk, 75 (0.1%) individuals developed gastric adenocarcinoma and 69 (0.1%) developed 
non-cardia gastric adenocarcinoma.  
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Table 1: Descriptive characteristics of the cohort of individuals receiving at least one 
eradication regimen for Helicobacter pylori in Sweden during 2005-2012. 
Characteristic 
 
 
 
Participants 
Number (%) 
Total 95,176 (100.0) 
Sex  
Men 44,028 (46.3) 
Women 51,148 (53.7) 
Age (years)  
18-59 57,214 (60.1) 
60-69 17,808 (18.7) 
≥ 70 20,154 (21.2) 
Calendar period  
2005-2006 21,218 (22.3) 
2007-2009 38,573 (40.5) 
2010-2012 35,385 (37.2) 
Place of residence  
Rural 23,686 (24.9) 
Urban 71,032 (74.6) 
Missing 458 (0.5) 
Type of cancer  
All gastric adenocarcinoma 75 (0.08) 
Non-cardia gastric adenocarcinoma 69 (0.07) 
Cardia adenocarcinoma 6 (0.01) 
Follow-up (years)  
Total 351,018 
Mean 3.7 
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Helicobacter pylori eradication treatment and risk of all gastric adenocarcinoma   
The SIRs decreased with longer time after eradication treatment. The SIRs were 8.65 (95% CI 
6.37-11.46) 1-3 years, 2.02 (95% CI 1.25-3.09) 3-5 years, and 0.31 (95% CI 0.11-0.67) 5-7.5 
years after eradication treatment (Table 2). Poisson regression with 1-3 years after eradication 
treatment as the reference group, showed IRRs of 0.05 (95% CI 0.03-0.09) 3-5 years and 0.00 
(95% CI 0.00-0.01) 5-7.5 years after eradication treatment. Analysis from the date of last 
eradication treatment (“per protocol”) showed a similar trend, with decreased risks from ≥5 
years after eradication treatment (data not shown). The risk of gastric adenocarcinoma 
increased with a higher number of eradication treatments, from SIR 1.88 (95% CI 1.44-2.41) 
in individuals with 1 eradication treatment to SIR 7.44 (95% CI 2.72-16.19) in those with 
more than 2 eradication treatments (Table 2). Poisson regression showed no difference in 
gastric adenocarcinoma risk between individuals residing in rural or urban areas (IRR 0.98, 
95% CI 0.59-1.61; p = 0.93).  
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Table 2: Risk of gastric and non-cardia gastric adenocarcinoma in individuals receiving 
Helicobacter pylori eradication treatment in Sweden from 2005-2012 compared to the 
Swedish standard population, expressed as standardized incidence ratio (SIR) with 95% 
confidence interval (CI)   
  Gastric adenocarcinoma 
Non-cardia gastric 
adenocarcinoma 
  Number  SIR (95% CI) Number  SIR (95% CI) 
Total 75 2.08 (1.63-2.60) 69 2.64 (2.06-3.35) 
Follow-up 
time, years   
 
  
1-3 48 8.65 (6.37-11.46) 43 10.74 (7.77-14.46) 
3-5 21 2.02 (1.25-3.09) 20 2.67 (1.63-4.13) 
5-7.5 6 0.31 (0.11-0.67) 6 0.43 (0.16-0.93) 
Number of 
eradications   
 
  
1 61 1.88 (1.44-2.41) 56 2.38 (1.80-3.10) 
2 8 2.84 (1.22-5.59) 7 3.45 (1.38-7.11) 
>2 6 7.44 (2.72-16.19) 6 10.47 (3.82-22.78) 
 
 
 
Women had a higher risk of gastric adenocarcinoma 1-3 years after eradication treatment (SIR 
11.69, 95% CI 7.49-17.40), compared to men (SIR 6.86, 95% CI 4.39-10.20), but the SIRs 
were similar after 3 years of follow-up (Table 3). Younger age was associated with a higher 
risk of gastric adenocarcinoma, especially 1-3 years after eradication treatment (Table 3).   
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Table 3: Risk of gastric adenocarcinoma in individuals receiving Helicobacter pylori eradication treatment in Sweden from 2005-2012 
compared to the Swedish standard population stratified by sex, age and calendar period, expressed as standardized incidence ratio (SIR) 
with 95% confidence interval (CI)  
Time after eradication 
  1-3 years 3-5 years 5-7.5 years 
  Number  SIR (95% CI) Number  SIR (95% CI) Number  SIR (95% CI) 
Total 48 8.65 (6.37-11.46) 21 2.02 (1.25-3.09) 6 0.31 (0.11-0.67) 
Sex   
 
    
Men 24 6.86 (4.39-10.20) 13 2.02 (1.08-3.46) 4 0.34 (0.09-0.87) 
Women 24 11.69 (7.49-17.40) 8 2.03 (0.87-4.00) 2 0.26 (0.03-0.93) 
Age, years   
 
    
18-59  14 25.71 (14.04-43.14) 4 3.57 (0.96-9.15) 0 NA 
60-69  8 5.95 (2.56-11.71) 4 1.52 (0.41-3.88) 1 0.18 (0.00-1.02) 
≥70  26 7.10 (4.64-10.40) 13 1.96 (1.05-3.36) 5 0.43 (0.14-1.00) 
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Helicobacter pylori eradication treatment and risk of non-cardia gastric 
adenocarcinoma   
The SIRs of non-cardia gastric adenocarcinoma decreased with longer duration after 
eradication treatment, with SIRs of 10.74 (95% CI 7.77-14.46) 1-3 years, 2.67 (95% CI 1.63-
4.13) 3-5 years, and 0.43 (95% CI 0.16-0.93) 5-7.5 years after eradication treatment (Table 2). 
Multiple eradication treatments increased the risk of non-cardia gastric adenocarcinoma, from 
SIR 2.38 (95% CI 1.80-3.10) in those with 1 eradication treatment to SIR 10.47 (95% CI 
3.82-22.78) in those with more than 2 eradication treatments (Table 2).  
 
Eradication treatment for H. pylori did not influence the overall risk of cardia adenocarcinoma 
(SIR 0.60, 95% CI 0.22-1.30), but there were too few cases (6 cases) to provide robust results 
regarding time latencies after eradication treatment of H. pylori and the risk of this tumour.  
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DISCUSSION 
This study showed that the risk of gastric adenocarcinoma and non-cardia gastric 
adenocarcinoma declined over time after eradication treatment for H. pylori and was lower 
than that of the background population from 5 years after eradication treatment.  
 
Methodological strengths of this study include the population-based design, large sample size, 
and the high-quality data in the registers used. Additionally, studies on this topic have rarely 
been performed on a Western population, thus this study assesses a gap of knowledge. Also, 
non-cardia gastric adenocarcinoma was analysed separately, the gastric cancer type known to 
be associated with H. pylori, which was not always the case in earlier studies. The study also 
has limitations. The registers do not contain information on some potential confounders, e.g. 
socioeconomic status. However, there was no effect of place of residence, which is correlated 
with socioeconomic status and lifestyle factors like smoking, diet, and physical activity. 
Another limitation was the relatively short duration of follow-up. However, the maximum 
length of follow-up was still 7.5 years and the study had sufficient statistical power for robust 
analyses, including in the longest follow-up category. The fact that parts of the background 
population were colonized with H. pylori would dilute the risk estimates, but not explain 
them, and this dilution should be limited because the population prevalence of H. pylori 
infection in Sweden is relatively low (15%).
5
 Additionally, the participants who received H. 
pylori eradication treatment were included in the background population, but because the 
study participants represented only a small proportion of the population (1.3%), this is 
unlikely to have had major influence on the results. If anything, it would again have diluted 
the associations, and not explain them. Another limitation is the lack of information about 
eradication treatments received before July 2005, making it unclear whether the first 
eradication date in the study was in fact the first eradication attempt. However, there is low 
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antibiotic resistance in Sweden,
17
 and only 9% of all cohort members received more than 1 
eradication treatment during the study period, making this a minor issue. There was no 
confirmation of eradication success, meaning that H. pylori might still have been present after 
treatment. This should explain the higher risk among individuals receiving multiple 
eradication treatments compared to those with only one (more likely to be successful) 
eradication treatment.  
  
The clearly decreasing risk after eradication treatment over time is reassuring and in line with 
the results of meta-analyses from predominantly Asian populations.
7,8
 Compared to previous 
cohort studies on this topic, where the largest studies included 3,781 individuals receiving H. 
pylori eradication treatment,
18
 this study is considerably larger. A randomized clinical trial 
included 1,130 individuals receiving eradication treatment with a maximum follow-up of 14.7 
years, where an odds ratio of 0.61 (95% CI 0.38-0.96) was found for gastric cancer, compared 
to a placebo group (n=1,128).
19
 However, that study did not analyse adenocarcinomas or non-
cardia cancers separately. Of all previous randomized clinical trials or cohort studies, only one 
was conducted in a Western population, i.e. in Finland with low prevalence of H. pylori and 
low risk of gastric cancer.
20
 The results of the present study are in line with the Finnish study, 
showing a strong decrease starting from the sixth year after eradication therapy. However, in 
this study adenocarcinoma was not assessed separately.  
 
In conclusion, this population-based Swedish cohort study showed a sharp decrease in risk of 
gastric adenocarcinoma and non-cardia gastric adenocarcinoma after eradication treatment for 
H. pylori. The risk was below the level of the background population 5 years after the 
eradication treatment. Thus, eradication treatment for H. pylori seems to prevent the 
development of gastric and non-cardia gastric adenocarcinoma also in Western populations.  
17 
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